Skip to main content
Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts. Wong, S. K., Whisenant, J. G., Bestvina, C. M., Berry, L. D., Owonikoko, T. K., Sanborn, R. E., Lammers, P., El Osta, B., Ramalingam, S. S., Carlisle, J. W., Steuer, C., Borghaei, H., Selvaggi, G., Shyr, Y., Wakelee, H. A., Horn, L., Beckermann, K. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.15_suppl.2578

View details for Web of Science ID 000708120601099